Levi & Korsinsky is investigating the Board of Directors of Cubist
Pharmaceuticals, Inc. (“Cubist Pharmaceuticals” or “the Company”)
(NasdaqGS:CBST) for possible breaches of fiduciary duty and other
violations of state law in connection with the sale of the Company to
Merck & Co.
Sign-up for CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. investment picks
Sign-up for SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. -- CBST investment picks
The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty and other violations of state law by the Board of
Directors of Cubist Pharmaceuticals, Inc. (“Cubist” or the “Company”)
(Nasdaq: CBST) relating to the proposed buyout of the Company by Merck &
Co., Inc. (“Merck”).
On December 8, 2014, Cubist and Merck announced the signing of a
definitive agreement pursuant to which Merck will acquire Cubist in a
transaction valued at approximately $9.5 billion.
Sign-up for SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information investment picks
Former United States Securities and Exchange Commission attorney Willie
Briscoe and the securities litigation firm of Powers
Taylor LLP are investigating potential claims against the Board of
Directors of Cubist Pharmaceuticals, Inc. (“Cubist”) (NASDAQ GS:CBST)
concerning the sale to Merck & Co., Inc. Under the terms of the
agreement, Cubist shareholders will receive $102.00 in cash for each
share owned, which is only a 37% premium over the share price just
before the deal was announced and only a slight premium over the 52-week
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating
whether members of the board of directors of Cubist Pharmaceuticals,
Inc. (NASDAQ: CBST) breached their fiduciary duties in connection with
the planned merger of the Company with Merck & Co., Inc. Cubist is
engaged in the research, development, and commercialization of
pharmaceutical products for medical needs in the acute care environment.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the
companies have entered into a definitive agreement under which Merck
will acquire Cubist for $102 per share in cash, which represents a 35
percent premium to Cubist’s average stock price for the most recent five
Sign-up for CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST investment picks
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.